Peregrine Ventures from Israel announced the closing of $115 million raising for its fourth fund, Peregrine 4. The partners include institutional and private equity investors from Israel, US, Europe and Australia. Peregrine 4 plans to invest in early stage and late stage rounds of medical technology startups in Israel. Since 2001, the VC firm has completed 10 exits totaling approximately $2 billion (cumulative value). . Prominent exits include Valtech, Neovasc, B-Balloon, Eximo and Rocketick.
Peregrine Ventures also owns and operates the Incentive Incubator in partnership with the Israeli Innovation Authority. Eyal Lifschitz, managing partner at Peregrine (photo above), noted: “There is a huge demand and opportunities in the Israeli medical technologies, and foreign investors recognize this. We decided to limit Peregrine 4 fund to $115 million, since we believe this size is best suit our management team and abilities to find the best opportunities – and to take an active role in helping them achieve their goals.”